531592
GENPHARMA
Start SIP
Invest Now
Start SIP in GENPHARMA
Performance
- Low
- ₹1
- High
- ₹1
- 52 Week Low
- ₹1
- 52 Week High
- ₹3
- Open Price₹1
- Previous Close₹1
- Volume463,171
- 50 DMA₹1.44
- 100 DMA₹1.61
- 200 DMA₹1.85
Investment Returns
- Over 1 Month -10.87%
- Over 3 Month -32.79%
- Over 6 Month -39.11%
- Over 1 Year -60.06%
Smart Investing Starts Here Start SIP with Genpharmasec for Steady Growth!
Genpharmasec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 124.4
- PEG Ratio
- -
- Market Cap Cr
- 68
- P/B Ratio
- 1
- Average True Range
- 0.07
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.05
- RSI
- 30.88
- MFI
- 59.42
Genpharmasec Financials
Genpharmasec Technicals
EMA & SMA
Current Price
₹1.23
-0.04
(-3.15%)
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹1.33
- 50 Day
- ₹1.44
- 100 Day
- ₹1.61
- 200 Day
- ₹1.85
Resistance and Support
1.24
- R3 1.34
- R2 1.31
- R1 1.27
- S1 1.20
- S2 1.17
- S3 1.13
Genpharmasec Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-06 | Quarterly Results | |
| 2025-09-02 | Others | Inter-alia, to consider 1. Fix the Day, Date, Time and approve Draft notice for the 33rd AGM of the Company. 2. The Directors Report for the year ended 31/03/2025. 3. Other business matters. issue of equity shares of Re. 1/- in the ratio of 1:1 @ premium of Re. 0.75/-. |
| 2025-08-07 | Quarterly Results | |
| 2025-05-21 | Audited Results | |
| 2025-03-24 | Independent Director Meeting |
Genpharmasec F&O
About Genpharmasec
- NSE Symbol
- GENPHARMA
- BSE Symbol
- 531592
- ISIN
- INE861N01036
Similar Stocks to Genpharmasec
Genpharmasec FAQs
Genpharmasec share price is ₹1 As on 13 January, 2026 | 07:46
The Market Cap of Genpharmasec is ₹68.1 Cr As on 13 January, 2026 | 07:46
The P/E ratio of Genpharmasec is 124.4 As on 13 January, 2026 | 07:46
The PB ratio of Genpharmasec is 1 As on 13 January, 2026 | 07:46
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.